| Literature DB >> 34199607 |
Mehmet Kanbay1, Begum Guler2, Lale A Ertuglu2, Tuncay Dagel1, Baris Afsar3, Said Incir4, Arzu Baygul5, Adrian Covic6, Ana Andres-Hernando7, Laura Gabriela Sánchez-Lozada8, Miguel A Lanaspa7, Richard J Johnson7.
Abstract
BACKGROUND: The consumption of sweetened beverages is associated with increased risk of metabolic syndrome, cardiovascular disease, and type 2 diabetes mellitus.Entities:
Keywords: copeptin; fibroblast growth factor 21; osmolarity; sugary beverage
Year: 2021 PMID: 34199607 PMCID: PMC8228203 DOI: 10.3390/nu13061916
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram of the study design.
Baseline characteristics of the study population.
| Characteristics | 30 Healthy Subjects | |||
|---|---|---|---|---|
| Overall | Group 1 | Group 2 |
| |
| Number | 30 | 15 | 15 | |
| Age, years (mean ± SD) | 26.1 | 25.33 ± 1.8 | 26.9 ± 4.9 | 0.7 |
| Gender (male) n (%) | 13 (43.3%) | 6 (40%) | 7 (46.7%) | 0.9 |
| Smoking, n (%) | 4 (13.3%) | 2 (13.3%) | 2 (13.3%) | 0.9 |
| BMI, kg/m2 (median ± IQR) | 22.9 | 22.86 ± 6.3 | 22.9 ± 2.1 | 0.8 |
| Systolic BP (mmHg) |
109.2 (105.9 | 108.5 (104.8 ± 112.2) | 109.5 (105.8 ± 113.2) | 0.9 |
| Diastolic BP (mmHg) | 74.2 (70.9 ± 76.3) | 74.5 (70.8 ± 76.8) | 73.9 (70.9 ± 75.9) | 0.9 |
| Hemoglobin (median ± IQR) | 14.4 | 14.1 ± 2.5 | 14.6 ± 3.1 | 0.5 |
| ALT-U/L (median ± IQR) | 12.9 | 11 ± 9.2 | 14.3 ± 22.7 | 0.1 |
| GGT-U/L (median ± IQR) | 12 | 12 ± 8 | 12 ± 13 | 0.8 |
| Creatinine-mg/dL (median ± IQR) | 0.7 | 0.7 ± 0.2 | 0.8 ± 0.3 | 0.5 |
p < 0.05 is significant. BMI—body mass index, BP—blood pressure, IQR—interquartile range, ALT—alanine aminotransferase, GGT—gamma-glutamyl transferase.
Serum glucose, insulin, HOMA-IR (homeostatic model assessment) score, FGF-21 (fibroblast growth factor), copeptin, osmolarity, sodium, BUN (blood urea nitrogen), lactate, uric acid, and phosphate levels after the ingestion of 500 mL of apple juice over time.
| Baseline | 15 min | 30 min | 60 min | 120 min | |||
|---|---|---|---|---|---|---|---|
| Glucose (mg/dL) | <0.001 | <0.001 | |||||
| Group 1 | 66.4 ± 6.3 | 76 ± 18 | 84.6 ± 10 | 86.1 ± 1.5 | 76.6 ± 15.1 | ||
| Group 2 | 78 ± 18.7 | 102.5 ± 17.3 | 113.6 ± 25 | 85.3 ± 30.2 | 77.8 ± 9.2 | ||
| Insulin (μIU/mL) | <0.001 | 0.001 | |||||
| Group 1 | 8.4 ± 5.5 | 15.8 ± 10.5 | 33.8 ± 21.7 | 48.3 ± 35.8 | 10.7 ± 5.9 | ||
| Group 2 | 11.9 ± 7.4 | 35.7 ± 19.4 | 49 ± 36.2 | 24.7 ± 24.4 | 8.7 ± 7.4 | ||
| HOMA-IR score | <0.001 | <0.001 | |||||
| Group 1 | 1.7 ± 1.0 | 4.5 ± 4.0 | 7.9 ± 3.9 | 11 ± 5.7 | 3.1 ± 4.4 | ||
| Group 2 | 2.0 ± 1.0 | 12.3 ± 9.6 | 15.4 ± 10.9 | 8.0 ± 4.1 | 3.3 ± 2.2 | ||
| FGF-21 (pg/mL) | <0.001 | <0.001 | |||||
| Group 1 | 16.4 ± 17.2 | 20.5 ± 13.7 | 22.1 ± 16.2 | 24.5 ± 15.6 | 18.9 ± 14.1 | ||
| Group 2 | 18.3 ± 15.4 | 31 ± 12.7 | 36.8 ± 11.2 | 43.9 ± 17.1 | 25.4 ± 17.2 | ||
| Copeptin (pmol/L) | <0.001 | 0.044 | |||||
| Group 1 | 45.6 ± 52.9 | 56.5 ±46.8 | 60.1 ± 52.4 | 54.8 ± 53 | 47.9 ± 35.9 | ||
| Group 2 | 58.5 ± 61.8 | 98.7 ± 64.6 | 99.2 ± 57.6 | 74.7 ± 60.9 | 60.4 ± 30.2 | ||
| Osmolarity (mOsm/L) | <0.001 | <0.001 | |||||
| Group 1 | 283.7 ± 5.6 | 284.5 ± 8.7 | 283.9 ± 6.5 | 284.5 ± 6.6 | 284.9 ± 7.9 | ||
| Group 2 | 284.7 ± 5.4 | 289.2 ± 6.6 | 291.8 ± 4.9 | 289.8 ± 6.8 | 286.2 ± 5.3 | ||
| Sodium (mmol/L) | <0.001 | <0.001 | |||||
| Group 1 | 137.6 ± 1.8 | 137.9 ± 2.0 | 138 ± 1.6 | 137.9 ± 1.5 | 138.2 ± 1.7 | ||
| Group 2 | 138.1 ± 1.2 | 140.2 ± 1.0 | 141.9 ± 0.8 | 139.7 ± 0.8 | 138.5 ± 1.2 | ||
| BUN (mg/dL) | <0.001 | <0.001 | |||||
| Group 1 | 11.9 ± | 11.7 ± 4.0 | 11.8 ± 3.9 | 11.3 ± 3.6 | 10.5 ± 3.2 | ||
| Group 2 | 12.7 ± 4.0 | 15.3 ± 3.4 | 18.1 ± 4.0 | 14.5 ± 3.2 | 11.6 ± 3.5 | ||
| Lactic acid (mmol/L) | <0.001 | <0.001 | |||||
| Group 1 | 0.9 ± 0.5 | 1 ± 0.4 | 1.5 ± 0.5 | 1.9 ± 0.7 | 1.2 ± 0.4 | ||
| Group 2 | 1 ± 0.4 | 1.8 ± 0.4 | 2.6 ± 0.8 | 2.5 ± 0.8 | 1.4 ± 0.7 | ||
| Phosphate (mg/dL) | 0.022 | <0.001 | |||||
| Group 1 | 3.4 ± 0.8 | 3.4 ± 0.7 | 3.5 ± 0.6 | 3.4 ± 0.7 | 3.5 ± 0.8 | ||
| Group 2 | 3.5 ± 0.4 | 3.7 ± 0.2 | 3.9 ± 0.3 | 3.9 ± 0.7 | 3.8 ± 0.7 | ||
| Uric acid (mg/dL) | <0.001 | 0.48 | |||||
| Group 1 | 4.3 ± 1.5 | 4.3 ± 1.4 | 4.5 ± 1.7 | 4.6 ± 1.7 | 4.5 ± 1.7 | ||
| Group 2 | 4.4 ± 1.1 | 4.6 ± 1.1 | 4.7 ± 0.9 | 4.8 ± 1.1 | 4.6 ± 1.3 | ||
Data are presented as the mean (95% CI) at baseline and least-squares mean (95% CI) at 15, 30, 60, and 120 min. Analysis was conducted using a mixed model for repeated measures, adjusting for baseline values. a p-Values for effect trend over time in all arms (repeated-measures ANOVA). b p-Values for treatment × time interaction, evaluated if changes in Group 1 were different from changes in Group 2 (repeated-measures ANOVA).
Figure 2Changes in plasma glucose (A), plasma insulin (B), HOMA-IR (homeostatic model assessment) (C), and FGF-21 (fibroblast growth factor 21) (D) values in group 1 and group 2.
The differences in glucose, insulin, HOMA-IR (homeostatic model assessment) score, FGF-21 (fibroblast growth factor), copeptin, osmolarity, sodium, BUN (blood urea nitrogen), lactate, uric acid, and phosphate levels compared with baseline after 500 mL of juice ingestion.
| Baseline–15 min | Baseline–30 min | Baseline–60 min | Baseline–120 min | |
|---|---|---|---|---|
| Glucose (mg/dL) | ||||
| Group 1 | 11.6 ± 9.2 | 20.5 ± 7.9 | 19.7 ± 13.7 | 8.3 ± 112.7 |
| Group 2 | 31.7 ± 14.7 | 38.2 ± 13.4 | 13.6 ± 15.7 | 6.7 ± 8.3 |
| <0.001 | <0.001 | 0.213 | 0.983 | |
| Insulin (μIU/mL) | ||||
| Group 1 | 11.4 ± 13.5 | 22.9 ± 12.8 | 33.9 ± 20.1 | 6.1 ± 20.2 |
| Group 2 | 35.8 ± 31.3 | 42.9 ± 30.2 | 18.6 ± 15.4 | 1.9 ± 6.8 |
| 0.004 | 0.033 | 0.019 | 0.494 | |
| HOMA-IR (Homeostatic model assessment) | ||||
| Group 1 | 2.9 ± 3.7 | 6.2 ± 3.6 | 9.4 ± 6.1 | 1.5 ± 4.6 |
| Group 2 | 10.3 ± 9.8 | 13.4 ± 10.7 | 6.0 ± 4.2 | 1.2 ± 1.8 |
| 0.003 | 0.040 | 0.078 | 0.494 | |
| FGF-21 (pg/mL) | ||||
| Group 1 | 3.7 ± 7.1 | 6.6 ± 7.5 | 6.5 ± 6.9 | −1.3 ± 8.7 |
| Group 2 | 14.8 ± 7.5 | 21.9 ± 7.4 | 24.5 ± 11.7 | 8.9 ± 8.4 |
| <0.001 | <0.001 | <0.001 | 0.001 | |
| Copeptin (pmol/L) | ||||
| Group 1 | 18.8 ± 30.6 | 23.3 ± 36.4 | 20.3 ± 31.9 | 2.6 ± 10.6 |
| Group 2 | 35.2 ± 24.1 | 46.2 ± 28 | 20.2 ± 24.2 | 2.7 ± 15.4 |
| 0.005 | 0.001 | 0.576 | 0.604 | |
| Osmolarity (mOsm/L) | ||||
| Group 1 | 0.5 ± 2.5 | 1.2 ± 1.5 | 1.3 ± 1.3 | 0.8 ± 2 |
| Group 2 | 5.1 ± 2.3 | 6.4 ± 2.1 | 4.3 ± 3.7 | 1.5 ± 2.3 |
| <0.001 | <0.001 | 0.044 | 0.494 | |
| Sodium (mmol/L) | ||||
| Group 1 | 2.9 ± 3.7 | 6.2 ± 3.6 | 9.4 ± 6.1 | 1.5 ± 4.6 |
| Group 2 | 10.3 ± 9.8 | 13.4 ± 10.7 | 6.0 ± 4.2 | 1.2 ± 1.8 |
| 0.002 | <0.001 | 0.013 | 0.656 | |
| BUN (mg/dL) | ||||
| Group 1 | 0.3 ± 1.7 | 0.4 ± 1.4 | 0.3 ± 1.2 | 0.6 ± 1.7 |
| Group 2 | 2.1 ± 0.9 | 3.8 ± 1.0 | 1.6 ± 1.2 | 0.3 ± 1.2 |
| <0.001 | <0.001 | 0.003 | 0.827 | |
| Lactic acid (mmol/L) | ||||
| Group 1 | 0.1 ± 0.3 | 0.6 ± 0.5 | 1.1 ± 0.6 | 0.5 ± 0.7 |
| Group 2 | 0.7 ± 0.3 | 1.5 ± 0.5 | 1.5 ± 0.5 | 1.5 ± 0.4 |
| <0.001 | <0.001 | 0.04 | 0.351 | |
| Phosphate (mg/dL) | ||||
| Group 1 | −0.1 ± 0.2 | −0.1 ± 0.1 | −0.2 ± 0.3 | 0.04 ± 0.5 |
| Group 2 | 0.1 ± 0.1 | 0.3 ± 0.2 | 0.4 ± 0.3 | 0.3 ± 0.2 |
| 0.001 | <0.001 | <0.001 | 0.026 | |
| Uric acid (mg/dL) | ||||
| Group 1 | 0.1 ± 0.1 | 0.2 ± 0.3 | 0.3 ± 0.3 | 0.3 ± 0.3 |
| Group 2 | 0.1 ± 0.2 | 0.3 ± 0.9 | 0.4 ± 0.3 | 0.2 ± 0.3 |
| 0.931 | 0.308 | 0.411 | 0.675 | |
Figure 3Changes in plasma copeptin (A), plasma osmolarity (B), sodium (C), and BUN (blood urea nitrogen) (D) values in group 1 and group 2.
Figure 4Changes in plasma lactic acid (A), plasma uric acid (B), and phosphate (C) values in group 1 and group 2.